Clinical Trials Browser

bicalutamide × Clear all

NCT07593079 2026-05-18

Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer

Phase 2 Not yet recruiting

Prostatic Neoplasms

NCT00544830 2026-05-15

Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer

Phase 2 Active not recruiting

29 enrolled 12 charts

PSA Level Greater Than Two

NCT07455903 2026-05-13

Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT

Phase 2 Recruiting

Prostatic Neoplasms

NCT02531516 2026-05-08

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT03070886 2026-05-07

Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery

Phase 2/3 Completed

Stage I Prostate Adenocarcinoma AJCC v7

NCT05521698 2026-05-05

A Randomized Trial of Bicalutamide in Non-Muscle Invasive Bladder Cancer

Phase 1 Recruiting

Non-Muscle Invasive Bladder Urothelial Carcinoma

NCT04513717 2026-05-04

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT05050084 2026-05-04

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

Phase 3 Active not recruiting

Prostate Adenocarcinoma

NCT01251861 2026-04-29

Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer

Phase 2 Active not recruiting

108 enrolled 16 charts

Prostatic Neoplasms

NCT02346253 2026-04-13

High-Dose Brachytherapy in Treating Patients With Prostate Cancer

Phase NA Active not recruiting

Prostatic Neoplasms

NCT03650894 2026-04-13

Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients

Phase 2 Active not recruiting

Breast Neoplasms

NCT05095207 2026-04-13

Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer

Phase 1/2 Recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT04787744 2026-04-08

VA STARPORT

Phase 2/3 Recruiting

Neoplasm Metastasis, Prostatic Neoplasms

NCT06145308 2026-04-02

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

Phase 2 Recruiting

Salivary Gland Neoplasms

NCT06222593 2026-04-01

Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination With Sunitinib in Patients With TKIs-resistant RCC

Phase 1/2 Recruiting

Carcinoma, Renal Cell

NCT06365788 2026-04-01

ABBICAR

Phase 2 Recruiting

Bulbo-Spinal Atrophy, X-Linked, Triple Negative Breast Neoplasms

NCT00936390 2026-03-06

Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

Phase 3 Completed

1,538 enrolled 37 charts

Prostatic Neoplasms

NCT01546987 2026-03-06

Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

Phase 3 Completed

239 enrolled 38 charts

Prostatic Neoplasms

NCT05700903 2026-03-02

ARCH

Phase 4 Completed

Hypertension, Kidney Diseases, Prostatic Neoplasms, Primary Dysautonomias

NCT04943536 2026-02-27

BiolenRT

Phase 1 Active not recruiting

Prostate Adenocarcinoma

NCT06650579 2026-02-24

REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial

Phase 3 Recruiting

Prostatic Neoplasms

NCT01786265 2026-02-20

Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT07393867 2026-02-06

ARPEGGIO

Phase 2 Not yet recruiting

Prostatic Neoplasms

NCT04734730 2026-01-28

Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer

Phase 2 Recruiting

Prostatic Neoplasms

NCT03090165 2026-01-02

Ribociclib and Bicalutamide in AR+ TNBC

Phase 1/2 Active not recruiting

Triple Negative Breast Neoplasms

NCT01809691 2025-12-31

S1216

Phase 3 Completed

1,313 enrolled 22 charts

Prostatic Neoplasms

NCT03809000 2025-12-30

STEEL

Phase 2 Active not recruiting

188 enrolled 25 charts

Prostatic Neoplasms

NCT03009981 2025-12-18

A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

Phase 3 Completed

Prostatic Neoplasms

NCT05327647 2025-12-18

BicaBCa

Phase 2 Recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT04025372 2025-12-15

INTREPId (INTermediate Risk Erection PreservatIon Trial)

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT04034095 2025-12-15

A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan

Prostatic Neoplasms

NCT06528210 2025-09-23

Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer

Phase 2 Withdrawn

Prostatic Neoplasms

NCT03678025 2025-09-11

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

Phase 3 Recruiting

Prostatic Neoplasms

NCT03348670 2025-08-17

Drugs-SNPs

Phase 2/3 Active not recruiting

Neoplasms, Prostatic Neoplasms

NCT07117851 2025-08-12

A Study of Disitamab Vedotin + Bicalutamide in HER2/AR-Positive Scrotal Paget's Disease

Phase 2 Recruiting

Paget Disease, Extramammary

NCT06501911 2025-07-22

A Study of Bicalutamide With Brain Re-irradiation to Treat Recurrent/Progressive High Grade Glioma

Phase 1 Withdrawn

Glioblastoma, Glioma

NCT02605486 2025-07-03

Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC)

Phase 1/2 Active not recruiting

Breast Neoplasms

NCT01342367 2025-06-10

Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer

Phase NA Active not recruiting

74 enrolled 12 charts

Prostatic Neoplasms

NCT00328614 2025-05-16

Samarium-153 With Neoadjuvant Hormonal and Radiation Therapy for Locally Advanced Prostate Cancer

Phase 1 Completed

32 enrolled 12 charts

Prostatic Neoplasms

NCT01420250 2025-05-15

Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer

Phase 1 Completed

Prostatic Neoplasms

NCT00567580 2025-05-09

Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer

Phase 3 Active not recruiting

1,792 enrolled 27 charts

Prostatic Neoplasms

NCT00223145 2025-01-27

PCS III

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT02299999 2025-01-15

SAFIR02_Breast

Phase 2 Active not recruiting

Breast Neoplasms

NCT01288911 2024-12-06

A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer

Phase 2 Completed

375 enrolled 24 charts

Neoplasm Metastasis, Neoplasms, Prostatic Neoplasms

NCT02366494 2024-11-25

Micro RNAs to Predict Response to Androgen Deprivation Therapy

Prostatic Neoplasms

NCT01969578 2024-11-05

Androgen Deprivation Therapy in Advanced Salivary Gland Cancer

Phase 2 Completed

Adenocarcinoma, Salivary Gland Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT04284761 2024-06-24

Biolen-PC

Phase 1 Completed

Lower Urinary Tract Symptoms

NCT03141671 2024-05-14

Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT03358563 2024-05-03

Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer

Phase EARLY_PHASE1 Completed

Prostatic Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis